Question 1

What is medical writing software?

Accepted Answer

Medical writing software is an authoring environment for the scientific narratives that sit inside regulatory submissions: clinical study reports (CSRs), patient narratives, clinical overviews and summaries, investigator brochures, and publications. It differs from general writing tools by supporting ICH E3-structured CSR templates, linked citations to clinical study data, standardized language libraries across programs, and review workflows that span Medical, Regulatory Affairs, Clinical, and Biostatistics. It also supports 21 CFR Part 11 electronic signatures for regulated outputs.

Question 2

How is medical writing different from regulatory writing?

Accepted Answer

Regulatory writing is broader: it covers Module 1 administrative content, Module 2 summaries, deficiency responses, briefing documents, and any other submission-adjacent writing. Medical writing is the subset focused on scientific narratives, especially CSRs, patient narratives, and Module 2.5/2.7 clinical summaries. In practice the two disciplines overlap heavily, and the same writer often handles both. Assyro supports both workflows in the same platform because the underlying work (linked citations, tracked review, version control, audit trail) is identical.

Question 3

Can Assyro auto-generate patient narratives?

Accepted Answer

Yes. Given structured clinical data (SDTM or ADaM datasets), Assyro generates patient narratives that match your CSR narrative template, include required adverse event and concomitant medication detail, and preserve consistent language across hundreds of narratives. Writers review and edit the drafts; the time savings are in the initial generation and in the consistency of language across the narrative set. Auto-generation is not a replacement for medical judgment on complex cases but is a significant accelerator for routine narratives.

Question 4

Does medical writing software need to be 21 CFR Part 11 compliant?

Accepted Answer

Yes when it is used to produce documents that become part of a GxP-regulated submission or quality system. Assyro operates as 21 CFR Part 11-ready: electronic signatures, audit trails, controlled access, system validation, and retention are all supported. Teams that treat medical writing as a non-GxP activity (because the final document lives in the DMS of record, not in the writing tool) still benefit from the controls but may not formally validate the writing tool against Part 11.

Question 5

Can multiple medical writers collaborate on the same CSR?

Accepted Answer

Yes. A CSR typically has 4-8 contributing writers across clinical, statistical, and medical sections. Assyro supports concurrent editing with section-level locks, so section authors work in parallel without overwriting each other's changes. Comments and review tasks route to specific sections and specific reviewers. The final document is assembled from section modules with an audit trail showing who wrote, reviewed, and approved each part.

Question 6

How does Assyro handle scientific claim consistency?

Accepted Answer

Claim libraries capture approved scientific statements (mechanism of action, pivotal efficacy statements, safety profile summaries) with their underlying evidence and approval status. When a writer uses a claim, the platform tracks the use, ensures the language matches the approved version, and flags when upstream evidence changes require the claim to be re-evaluated. This prevents the 'same claim worded three different ways in three modules' problem that slows cross-functional review.

Question 7

Does Assyro replace Veeva MedComms or PleaseReview?

Accepted Answer

Assyro covers the medical writing authoring and review workflow, which overlaps with the scope of Veeva MedComms and the review coordination scope of PleaseReview. Teams with heavy existing Veeva investment sometimes use Assyro for AI-assisted drafting and coordination while publishing finalized documents to Veeva as the DMS of record. Teams using PleaseReview for review coordination often replace it entirely once Assyro's review workflow is in place.

Question 8

Is medical writing software necessary for a small biotech?

Accepted Answer

For a biotech running its first IND through Phase 2, the writing workflow usually fits in Word plus SharePoint, and medical writing is often outsourced to a CRO or a freelance writer. The case for dedicated software strengthens around Phase 3 and the first major NDA/BLA filing, when the volume of CSRs, the coordination across writers, and the regulatory stakes all escalate. Small biotechs that use Assyro earlier tend to do so because they want to avoid rebuilding the writing workflow from scratch at the NDA stage, not because the Phase 1 volume requires it.

Medical Writing Software

How Medical Writing Fits the Submission Workflow

Close the Medical-to-Regulatory Language Gap

Draft Patient Narratives From Structured Source Data

Reuse Approved Language by Indication and Jurisdiction

Cut Medical Affairs Review From 3 Weeks to 1

Controls and Traceability for Medical Writing

Keep Medical Writing Audit-Ready

Scale Across Programs Without Adding Complexity

Questions About Medical Writing

See Medical Writing in a Live Submission Workflow.